Your browser doesn't support javascript.
loading
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.
Deniz, Miriam; DeGregorio, Amelie; DeGregorio, Nikolaus; Bekes, Inga; Widschwendter, Peter; Schochter, Fabienne; Ernst, Kristina; Scholz, Christoph; Bauer, Emanuel Ca; Aivazova-Fuchs, Viktoria; Weissenbacher, Tobias; Kost, Bernd; Jueckstock, Julia; Andergassen, Ullrich; Steidl, Julia; Trapp, Elisabeth; Fasching, Peter A; Häberle, Lothar; Beckmann, Matthias W; Schneeweiss, Andreas; Schrader, Iris; Janni, Wolfgang; Rack, Brigitte; Friedl, Thomas Wp.
Afiliação
  • Deniz M; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: miriam.deniz@uniklinik-ulm.de.
  • DeGregorio A; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: amelie.degregorio@uniklinik-ulm.de.
  • DeGregorio N; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: nikolaus.degregorio@uniklinik-ulm.de.
  • Bekes I; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: inga.bekes@uniklinik-ulm.de.
  • Widschwendter P; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: peter.widschwendter@uniklinik-ulm.de.
  • Schochter F; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: fabienne.schochter@uniklinik-ulm.de.
  • Ernst K; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: kristina.ernst@uniklinik-ulm.de.
  • Scholz C; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: christoph.scholz@uniklinik-ulm.de.
  • Bauer EC; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: emanuel.bauer@uniklinik-ulm.de.
  • Aivazova-Fuchs V; Klinik Bad Trissl GmbH, Bad-Trissl-Straße 73, 83080 Oberaudorf, Germany. Electronic address: Viktoria.Aivazova@klinik-bad-trissl.de.
  • Weissenbacher T; Department of Gynecology and Obstetrics, Campus Innenstadt Ludwig Maximilian University Munich, Maistrasse 11, 80539 Munich, Germany. Electronic address: weissenbacher@mic-zentrum-muenchen.de.
  • Kost B; Department of Gynecology and Obstetrics, Campus Innenstadt Ludwig Maximilian University Munich, Maistrasse 11, 80539 Munich, Germany. Electronic address: bernd.kost@med.uni-muenchen.de.
  • Jueckstock J; Department of Gynecology and Obstetrics, Campus Innenstadt Ludwig Maximilian University Munich, Maistrasse 11, 80539 Munich, Germany. Electronic address: julia.jueckstock@med.uni-muenchen.de.
  • Andergassen U; Department of Gynecology and Obstetrics, Campus Innenstadt Ludwig Maximilian University Munich, Maistrasse 11, 80539 Munich, Germany. Electronic address: ullrich.andergassen@med.uni-muenchen.de.
  • Steidl J; Department of Gynecology and Obstetrics, Campus Innenstadt Ludwig Maximilian University Munich, Maistrasse 11, 80539 Munich, Germany. Electronic address: julia.Steidl@med.uni-muenchen.de.
  • Trapp E; Department of Gynecology and Obstetrics, Campus Innenstadt Ludwig Maximilian University Munich, Maistrasse 11, 80539 Munich, Germany. Electronic address: elisabeth.trapp@med.uni-muenchen.de.
  • Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Schloßplatz 4, 91054 Erlangen, Germany. Electronic address: Peter.Fasching@uk-erlangen.de.
  • Häberle L; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Schloßplatz 4, 91054 Erlangen, Germany. Electronic address: lothar.haeberle@uk-erlangen.de.
  • Beckmann MW; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Schloßplatz 4, 91054 Erlangen, Germany. Electronic address: Matthias.beckmann@uk-erlangen.de.
  • Schneeweiss A; Department of Gynecology and Obstetrics, University of Heidelberg, Grabengasse 1, 69117 Heidelberg, Germany. Electronic address: Andreas.Schneeweiss@med.uni-heidelberg.de.
  • Schrader I; Gynecologic-Oncological Office, Pelikanplatz 23, 30177 Hannover, Germany. Electronic address: info@goph.de.
  • Janni W; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: wolfgang.janni@uniklinik-ulm.de.
  • Rack B; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: brigitte.rack@uniklinik-ulm.de.
  • Friedl TW; Department of Gynecology and Obstetrics, University Ulm, Prittwitzstr. 43, 89075 Ulm, Germany. Electronic address: thomas.friedl@uniklinik-ulm.de.
Breast ; 44: 81-89, 2019 Apr.
Article em En | MEDLINE | ID: mdl-30690254
ABSTRACT

OBJECTIVES:

In breast cancer, large tumor size, positive nodal stage and a triple-negative tumor subtype are associated with reduced survival, but the interactions between these prognostic factors are not well understood. MATERIAL AND

METHODS:

Here we re-evaluated the impact of tumor size, nodal stage and tumor subtype on disease-free survival (DFS), overall survival (OS), distant disease-free survival (DDFS) and breast cancer specific survival (BCSS) in a retrospective analysis using data from the adjuvant SUCCESS A trial. Subgroup analyses were conducted to assess whether the effect of tumor size and nodal stage on survival depended on tumor subtype.

RESULTS:

Increasing tumor size, higher nodal stage and triple negative breast cancer (TNBC) were associated with unfavorable prognosis (all p < 0.001). There was no significant interaction between tumor subtype and tumor size (p > 0.5 for all four survival endpoints), but we found significant interactions between tumor subtype and nodal stage (p < 0.05 for all four survival endpoints), with no differences in survival among tumor subtypes for patients with pN0 tumors (all p > 0.05) and pronounced differences in survival among tumor subtypes for patients with positive nodal stage (all p < 0.001).

CONCLUSIONS:

This analysis confirms tumor size, nodal stage and tumor subtype as independent prognostic factors in high-risk early breast cancer. Nodal-positive patients with TNBC had a considerably worse outcome compared to nodal-positive patients with another tumor subtype. This underlines the importance for early detection particularly for patients with TNBC. TRIAL REGISTRATION EudraCT 2005-000490-21; ClinicalTrials.gov Identifier NCT02181101.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sobreviventes de Câncer Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Sobreviventes de Câncer Idioma: En Ano de publicação: 2019 Tipo de documento: Article